Prediction of Sudden Cardiac Arrest After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: ASA-SCARRE Risk Score.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
01 12 2022
Historique:
received: 23 06 2022
revised: 09 08 2022
accepted: 17 08 2022
pubmed: 4 10 2022
medline: 2 11 2022
entrez: 3 10 2022
Statut: ppublish

Résumé

This study aimed to derive a new score, the Alcohol Septal Ablation-Sudden Cardiac ARREst (ASA-SCARRE) risk score, that can be easily used to evaluate the risk of sudden cardiac arrest events (sudden cardiac death, resuscitation, or appropriate implantable cardioverter-defibrillator discharge) after alcohol septal ablation (ASA) in patients with hypertrophic obstructive cardiomyopathy. We analyzed 1,834 patients from the Euro-ASA registry (49% men, mean age 57 ± 14 years) who were followed up for 5.0 ± 4.3 years (9,202 patient-years) after ASA. A total of 65 patients (3.5%) experienced sudden cardiac arrest events, translating to 0.72 events per 100 patient-years. The independent predictors of sudden cardiac arrest events were septum thickness before ASA (hazard ratio 1.09 per 1 mm, 95% confidence interval 1.04 to 1.14, p <0.001) and left ventricular outflow tract (LVOT) gradient at the last clinical checkup (hazard ratio 1.01 per 1 mm Hg, 95% confidence interval 1.01 to 1.02, p = 0.002). The following ASA-SCARRE risk scores were derived and independently predicted long-term risk of sudden cardiac arrest events: "0" for both LVOT gradient <30 mmHg and baseline septum thickness <20 mm; "1" for LVOT gradient ≥30 mm Hg or baseline septum thickness ≥20 mm; and "2" for both LVOT gradient ≥30 mm Hg and baseline septum thickness ≥20 mm. The C statistic of the ASA-SCARRE risk score was 0.684 (SE 0.030). In conclusion, the ASA-SCARRE risk score may be a useful and easily available clinical tool to predict risk of sudden cardiac arrest events after ASA in patients with hypertrophic obstructive cardiomyopathy.

Identifiants

pubmed: 36192196
pii: S0002-9149(22)00910-9
doi: 10.1016/j.amjcard.2022.08.028
pii:
doi:

Substances chimiques

Ethanol 3K9958V90M

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

120-126

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosures The authors have no conflict of interests to declare.

Auteurs

Josef Veselka (J)

Department of Cardiology, University Hospital Motol, Second Medical School, Charles University, Prague, Czech Republic. Electronic address: veselka.josef@seznam.cz.

Max Liebregts (M)

Department of Cardiology, St. Antonius Hospital Nieuwegein, Nieuwegein, The Netherlands.

Robert Cooper (R)

Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.

Lothar Faber (L)

Department of Cardiology, Ruhr University Bochum, Bochum, Germany.

Jaroslav Januska (J)

Cardiocentre Podlesi, Trinec, Czech Republic.

Maksim Kashtanov (M)

Department of Endovascular Therapy, Sverdlovsk Regional Hospital No. 1 and Ural Federal University, Yekaterinburg, Russian Federation.

Klara Hulikova Tesarkova (KH)

Department of Demography and Geodemography, Faculty of Science, Charles University, Prague, Czech Republic.

Peter Riis Hansen (PR)

Department of Cardiology, Herlev and Gentofte Hospital, Hellerup, Denmark.

Hubert Seggewiss (H)

Comprehensive Heart Failure Center, University Clinic Wuerzburg, Wuerzburg, Germany.

Eugene Shloydo (E)

Department of Cardiology, City Hospital No. 2, St. Petersburg, Russian Federation.

Kirill Popov (K)

Department of Cardiology, City Hospital No. 2, St. Petersburg, Russian Federation.

Eva Hansvenclova (E)

Department of Cardiology, University Hospital Motol, Second Medical School, Charles University, Prague, Czech Republic.

Eva Polakova (E)

Department of Cardiology, University Hospital Motol, Second Medical School, Charles University, Prague, Czech Republic.

Jurriën Ten Berg (J)

Department of Cardiology, St. Antonius Hospital Nieuwegein, Nieuwegein, The Netherlands.

Rodney Hilton Stables (RH)

Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.

Jiri Jarkovsky (J)

Institute of Biostatistics and Analyses, Faculty of Medicine and Faculty of Science, Masaryk University, Brno, Czech Republic.

Jiri Bonaventura (J)

Department of Cardiology, University Hospital Motol, Second Medical School, Charles University, Prague, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH